NT-proBNP levels in the identification and classification of pulmonary transfusion reactions
- PMID: 32905629
- DOI: 10.1111/trf.16059
NT-proBNP levels in the identification and classification of pulmonary transfusion reactions
Abstract
Background: Consensus definitions for transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) have recently been revised; however, pulmonary transfusion reactions remain difficult to diagnose. We hypothesized that N-terminal pro-brain natriuretic peptide (NT-proBNP) levels could have utility in the identification and classification of pulmonary transfusion reactions.
Study design and methods: We performed a secondary analysis of a case-control study of pulmonary transfusion reactions at four academic hospitals. We evaluated clinical data and measured NT-proBNP levels prior to and following transfusion in patients with TACO (n = 160), transfused acute respiratory distress syndrome (ARDS) [n = 51], TRALI [n = 12], TACO/TRALI [n = 7], and controls [n = 335]. We used Wilcoxon Rank-Sum tests to compare NT-proBNP levels, and classification and regression tree (CART) algorithms to produce a ranking of covariates in order of relative importance for differentiating TACO from transfused controls.
Results: Pre-transfusion NT-proBNP levels were elevated in cases of transfused ARDS and TACO (both P < .001) but not TRALI (P = .31) or TACO/TRALI (P = .23) compared to transfused controls. Pre-transfusion NT-proBNP levels were higher in cases of transfused ARDS or TRALI with a diagnosis of sepsis compared to those without (P < .05 for both). CART analyses resulted in similar differentiation of patients with TACO from transfused controls for models utilizing either NT-proBNP levels (AUC 0.83) or echocardiogram results (AUC 0.80).
Conclusions: NT-proBNP levels may have utility in the classification of pulmonary transfusion reactions. Prospective studies are needed to test the predictive utility of pre-transfusion NT-proBNP in conjunction with other clinical factors in identifying patients at risk of pulmonary transfusion reactions.
© 2020 AABB.
References
REFERENCES
-
- Fatalities Reported to FDA Following Blood Collection and Transfusion 2018. https://www.fda.gov/media/136907/download. .
-
- Roubinian N. TACO and TRALI: Biology, risk factors, and prevention strategies. Hematology Am Soc Hematol Educ Program. 2018;2018(1):585-594.
-
- Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-2476.
-
- Wiersum-Osselton JC, Whitaker B, Grey S, et al. Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study. Lancet Haematol. 2019;6(7):e350-e358.
-
- Looney MR, Roubinian N, Gajic O, et al. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury. Crit Care Med. 2014;42(7):1676-1687.
Publication types
MeSH terms
Substances
Grants and funding
- L30 HL129355/HL/NHLBI NIH HHS/United States
- The authors were supported by research contracts from the National Heart, Lung, and Blood Institute (NHLBI Contracts HHSN2682011000002I, HHSN2682011000003I, HHSN2682011000004I, HHSN2682011000005I, and HHSN268201100006I for the Recipient Epidemiology and Donor Evaluation Study-III
- The authors were supported by research contracts from the National Heart, Lung, and Blood Institute (NHLBI Contracts HHSN2682011000002I, HHSN2682011000003I, HHSN2682011000004I, HHSN2682011000005I, and HHSN268201100006I for the Recipient Epidemiology and Donor Evaluation Study-III.
LinkOut - more resources
Full Text Sources
Research Materials
